INTRODUCTION
============

Major advances in the preceding decades have substantially improved the way cancer is treated. However, not every form of cancer has seen such profound benefits from the many advancements made. Successful treatment of high-grade gliomas (HGGs), which include glioblastomas (GBMs), remains particularly elusive. Current treatment typically involves surgical resection followed by tumor irradiation and chemotherapy. More than three decades of intensive research have produced only modest improvements in life expectancy ([@B100]). Life expectancy remains dismal, with GBM harboring a median survival time of 15 months ([@B63]) and a 5-year survival of just 9.8% ([@B107]). This poor prognosis is due in large part to the wide dissemination of tumor cells prior to diagnosis, which makes recurrence almost a certainty even after repeated resections ([@B8]). Conversely, less invasive gliomas typically result in long-term survival and are often curable ([@B48]).

The resilience of GBM due to diffuse infiltration has increased investigation into mechanisms of motility and invasion, with the goal of arresting or slowing glioma spread. This therapeutic goal may allow for more successful localized treatment with reduced recurrence. Broadly, cell migration starts with an extrinsic migratory signal, including chemical ([@B23]), mechanical ([@B62]), electrical ([@B17]), and other cues. Cells then define a leading edge in the direction of the migratory cue and a trailing edge at the rear. After cell polarization, actin polymerization at the leading edge causes protrusion of the plasma membrane. At the surface of the cell, transmembrane receptors, such as integrins, allow the cells to transmit forces generated from the interactions of myosin and the cytoskeleton to the extracellular microenvironment. These processes are summarized in [Figure 1](#F1){ref-type="fig"}. As such, valuable strategies for inhibiting glioma motility may include manipulation of migratory cues, cytoskeletal filaments and the myosin motors, transmembrane receptors, and the extracellular microenvironment. These can be grouped into extracellular and intracellular processes and factors, which will be reviewed in this article.

![Graphical summary of many of the factors involved in GBM invasion, presenting a GBM cell migrating away from the bulk tumor. GBM cells often migrate within perivascular spaces and along white matter tracts. Transmembrane receptors allow the cell to interact with both of these extracellular environments. The cytoskeleton rearranges to accommodate the directed migration down a migratory cue gradient, possibly including a chemokine gradient as depicted. Matrix metalloproteinases (MMPs) allow for remodeling of the extracellular matrix during migration. All of these factors present potential targets for halting GBM migration.](mbc-29-2509-g001){#F1}

EXTRACELLULAR FACTORS
=====================

Migratory cues
--------------

Tumor cells have been shown to respond to a variety of migratory cues, including chemotactic, galvanotactic, and mechanical cues ([@B86]). Glioma cells are no exception, and all of these cues are involved in glioma cell invasion. These migratory cues are being actively studied to increase the understanding of GBM migratory behavior and to find possible methods of intervention.

Chemotaxis is the process by which cells move in response to a chemical gradient, such as a cytokine, chemokine, or growth factor ([@B115]). In cancer, these pathways can be hijacked to aid in dissemination of tumor cells ([@B25]). Glioma cells are more susceptible to chemotactic cues than the healthy brain tissue due to up-regulation of chemokine receptors and growth factor receptors. Epidermal growth factor (EGF) receptors ([@B33]), platelet-derived growth factor (PDGF) receptors ([@B76]), and fibroblast growth factor (FGF) receptor 2 (Brockman *et al*., [@B15]; The Cancer Genome Atlas Research Network, [@B19]) often have genomic amplification in GBMs, which, among other oncogenic functions, can all lead to chemotaxis in response to their ligands. A variety of drugs targeting these migratory signals are being evaluated in clinical trials ([@B96]). The chemoattractant C-X-C ligand 12 (CXCL12, also known as stromal cell--derived factor 1, or SDF1) and its receptor C-X-C chemokine receptor 4 (CXCR4), which is required for brain development ([@B74]), also contribute to malignancy in a wide range of cancer variants, including gliomas. CXCR4 is highly up-regulated in invasive glioma tumor cells compared with noninvasive tumor cells ([@B32]). Treatment with a small molecular inhibitor of CXCR4 has been shown to suppress the growth of GBM tumors in vivo ([@B97]). In a model in which applied fluid flow enhanced migratory behavior, CXCR4 appeared to modulate glioma migratory behavior independent of CXCL12 ([@B72]). This is especially significant, as convection enhanced delivery (described by [@B27]), an experimental therapy popular in clinical trials, flows drugs directly into the tumor mass, which could theoretically increase glioma invasion. CXCR4 is being targeted in an ongoing clinical trial.

Concentrations of autocrine chemotactic cues would decrease with distance from the bulk tumor, limiting its potential impact at the tumor edge. It has been suggested, however, that normal astrocytes can secrete a host of chemokines and other promigratory proteins that have been shown to enhance migration of glioblastoma stem-like cells ([@B93]), which could provide chemotactic cues to invasive cells distal to the tumor mass. Additional methods through which healthy brain tissue could aid in glioma invasion and survival have been reviewed elsewhere ([@B95]). GBM cell migration toward the vasculature has also been proposed to be induced by gradients of the chemotactic peptide bradykinin, which is released by the vascular endothelial cells in the brain ([@B69]). Durotaxis, in which cells migrate down a substrate-rigidity gradient, has not been well characterized for glioma cells. The effects of other mechanical properties of the substrate, such as the arrangement of the physical features (nanotopography), have been well studied. Changes in topography can lead to changes in cytoskeletal organization, integrin expression, and cellular biophysical properties ([@B121]). Because of the importance of topography, it has been debated whether glioma cell migration paths are due to secreted biochemical cues or topography-related biomechanical cues. Both white matter tracts and the vasculature present, at least at the cellular scale, a linear pathway on which glioma cell migration can occur. Distant migration is less commonly found in the gray matter of the brain ([@B24]), which is characteristically a random, nonlinear ECM of the same components as white matter ([@B11]), so presenting a linear migratory pathway is thought to be able to induce the distant migration seen in the white matter. This theory was tested on electrospun poly(ε-caprolactone) (or PCL), nanofibers of linear or random organization. It was found that aligned fibers induced migration at over four times the velocity on randomly organized fibers ([@B52]). Changing the mechanical properties of the nanofibers also induced large changes in migration speed ([@B104]). Unexpectedly, at high cell densities on large width tracks velocity increases to the same level as seen on small linear tracks or in vivo. This calls into question whether mechanical confinement or the presence of linear tracks are the actual migratory cue ([@B70]). Regardless, these linear tracks were harnessed as migratory cues to guide brain tumor cells into a cytotoxic hydrogel, significantly reducing tumor volume, displaying potential clinical value ([@B51]).

Electrical cues also play a role in directed migration of GBM cells. Direct-current electric fields (dcEFs) occur endogenously and regulate numerous biological processes such as wound healing and embryogenesis ([@B78]). One method by which dcEFs affect these processes is galvanotaxis, in which directed cell migration occurs in a physiologically comparable dcEF toward either the anode or cathode ([@B73]). The mechanisms of galvanotaxis are still being explored, but it is postulated to depend on changes in intracellular Ca^2+^ concentrations and ion channel activities ([@B80]). In the brain, an endogenous dcEF was found to guide migration of neuroblasts from the subventricular zone to the olfactory bulb in adult mice ([@B21]). Owing to the galvanotactic response of these and other brain cells, it was therefore hypothesized that galvanotaxis may play a role in GBM invasion ([@B47]). In two dimensions (2D), all GBM subtypes tested showed anode-directed migration while neural progenitor cells displayed cathodic directedness. Another group found, however, that GBM cells switch preferences in three dimensions (3D), migrating toward the cathode instead of the anode ([@B101]). A recently popularized clinical treatment method of alternating, intermediate frequency electric currents, called tumor treating fields, could possibly inhibit migration through galvanotactic mechanisms ([@B2]).

Substrate
---------

The brain parenchyma contains a complex network of vasculature that traverses both the white matter and gray matter. White matter is composed of myelinated neuronal axons. In contrast, gray matter contains mostly unmyelinated nerve cell bodies and associated dendritic processes. As mentioned in the preceding section, HGG cells have been shown to migrate distantly in the perivascular spaces or down the white matter tracts, two components of the histological secondary structures of Scherer that characterize glioma invasion patterns ([@B102]). Histological images of glioma cells infiltrating perivascular and white matter microenvironments are seen in [Figure 2](#F2){ref-type="fig"}. This demonstrates the morphological plasticity of GBM cells, allowing them to inhabit the diverse extracellular environments present in the brain. Oligodendrocytes contain membrane-bound inhibitors of cell attachment that prevent most cells from spreading or migrating along the white matter tracts ([@B22]). This may account for much of the static, nonmigratory composition of the adult brain ([@B103]). Glioblastoma cells, however, are able to attach to and migrate along these cell surfaces, a behavior that was inhibited by metalloprotease blockers ([@B82]). As for the extracellular matrix, the basement membrane of the vasculature usually consists of fibronectin, collagen, and laminin. The extravascular brain parenchyma lacks any significant quantities of these extracellular matrix proteins, but instead consists primarily of hyaluronic acid (HA, also referred to as hyaluronan; [@B92]; [@B10]). The brain ECM and its effect on glioma invasion is further reviewed in Ferrer *et al*. (2018). The vastly different mechanisms required to traverse these different areas of the brain call into question whether glioma cells are intrinsically programmed to adapt to each environment or environmental selection leads to substrate-specific clonal evolution.

![Glioblastoma (GBM) migration patterns in brain parenchyma. (A) Perivascular migration. GBM cells adhere to and migrate along the canonical extracellular matrix proteins surrounding the vasculature. Hematoxylin and eosin (H&E) stained. (B) White matter infiltration of GBM cells showing elongated morphology between parallel bundles of axons in the white matter. Luxol fast blue myelin stain and H&E stain.](mbc-29-2509-g002){#F2}

Owing to frequent perivascular migration, angiogenesis was previously thought to be elicited by GBM cells. Anti-angiogenic agents are being actively investigated as a possible treatment mechanism, and have been shown to provide clinical efficacy, at least transiently, in a multitude of cancer types. However, treatment of GBM cells with a popular antibody that functionally inhibits VEGFR2, bevacizumab, has been shown to lead to very short-term cessation of invasion followed by a long-term increase of invasive behavior ([@B81]). Another group recapitulated these findings and showed that migration occurs on the preexisting brain microvessels, displacing the noncancerous cells in the perivascular space ([@B5]). This process was completely vascular endothelial growth factor (VEGF) independent.

To migrate efficiently through the dense extracellular space in the brain, GBM cells degrade and remodel the ECM. Matrix metalloproteinases (MMPs) are responsible for the degradation of the majority of ECM proteins, a process that has been previously reviewed in more detail ([@B12]). GBM cells have been shown to overexpress MMPs 2 and 9 ([@B35]) compared with healthy brain tissue, and overexpression of MMPs has been linked to increased GBM invasion and poor prognosis ([@B92]). Additionally, inhibition of MMPs has led to reduced glioma invasion in vitro ([@B110]). No clinical studies, however, have shown MMP inhibition to be effective in preventing glioma spread ([@B111]). This could be due to GBM cells secreting other ECM proteins, such as tenascin-C, fibronectin, vitronectin, and collagen, while degrading the native ECM and causing increased glioma cell migration ([@B30]). Additionally, the clonal expansion of glioma cells in the cell culture environment may eliminate the adaptation to different environments found in primary tumor cells. GBM cells were also shown to respond to changes in their mechanical environment with differential ECM assembly and MMP or HA synthase expression ([@B117]). HA is also much more abundant in glioma ECM than in the normal brain ([@B28]).

Even with degradation of the ECM, the brain parenchyma presents a severe mechanical challenge to migrating GBM cells. Cell processes are tightly packed in the brain parenchyma, with submicrometer pore sizes ([@B108]). To migrate through these environments, GBM cells adopt a migratory behavior similar to neural progenitor cells in which they extend a long process that defines the migratory pathway, followed by the nucleus and cell body ([@B9]). The nucleus of the cell deforms to allow migration through the pore. Movement of the nucleus through the pore, but not the leading process, was shown to require myosin II. In fact, they later showed that despite the abundance of promigratory factors involved in glioma migration, blocking myosin II effectively prevents migration of GBM in spatially constrained environments ([@B50]).

Cell migration is sensitive to the mechanical properties of the substrate (Pelham *et al*., 1997), and the brain presents unique mechanical challenges to migrating GBM cells. The brain is one of the most compliant tissues in the body. The Young's modulus ranges from several hundred pascals ([@B34]) to several kilopascals ([@B45]), depending on factors such as testing conditions, anatomical origin of the sample, postmortem time, and donor characteristics ([@B45]). There are also regions with sharp variations in stiffness, presenting a severe mechanical challenge to migration ([@B37]). The basement membrane of the perivascular region has a much higher stiffness than the brain parenchyma ([@B20]). GBM tumor cell lines have been shown to migrate rapidly on stiffer substrates, while failing to migrate effectively on compliant substrates with elastic moduli comparable to the brain parenchyma in 2D ([@B113]), and much lower migration velocities were seen in 3D ([@B4]). Another study, using a model of force transmission in cell migration, showed that the optimal stiffness for glioma cell migration was 100 kPa, 100-fold higher than that for optimal migration of healthy forebrain neurons and much higher than the brain parenchyma ([@B6]). The study showed that this increased response to stiff substrates was due to a much larger number of molecular motor clutches in glioma cells, and that softer substrates lead to a decrease in cell motility. These could explain the perivascular migratory behavior, but not how the cells can diffusely migrate through the much softer brain parenchyma. Engineered strategies for studying the effect of the microenvironment on glioblastoma have been extensively reviewed ([@B91]).

One potential explanation is that ECM secretion by migratory cells can regulate the cell response to the mechanical environment by inserting elastic fibrils between cells and the fabricated substrate. Presenting an elastic fibril between the cell and the substrate can even mediate the cell-sensed stiffness of the substrate ([@B118]), but this has not been extensively explored in regard to gliomas. The ECM does stiffen in response to increasing pressure ([@B89]) resulting from tissue expansion during tumor growth and the resistance to this expansion by the skull ([@B94]), and this in turn could also have profound effects on the stiffness sensed by the cells. Another explanation is that the established glioma cell lines do not accurately recapitulate the mechanosensitive behavior of primary tumor cells. In fact, of the three major subtypes of GBM, the majority of the commonly used cells lines are representative only of the mesenchymal subclass ([@B116]) and were used in the studies that showed an optimal substrate stiffness for migration to be higher than that of the brain parenchyma ([@B6]). Different primary glioma cells have diverse substrate migratory preferences, with some migrating dependently and others migrating independently of substrate stiffness ([@B42]). It has been postulated that these differing mechanosensitive behaviors could be subclass specific; GBM cell lines that migrated independent of rigidity were of the proneural subclass, which may be consistent with the fact that neurons branch mostly in a rigidity-independent manner ([@B40]).

INTRACELLULAR FACTORS
=====================

Cytoskeleton
------------

For cell migration to occur, the cytoskeletal structure must be conducive to migration. This is orchestrated by a combination of signaling pathways, which cause actin polymerization and myosin-based force that can be transmitted to the substrate. This process has been reviewed in more detail ([@B13]), and how it pertains to tumor invasion has also been reviewed in other sources ([@B38]). As such, cytoskeletal proteins and involved signaling pathways may be attractive targets for inhibiting glioma cell motility.

Radial glia cells ([@B39]; [@B77]) and glioma cells ([@B64]; Slhia *et al*., 2005) both exhibit decreases in migration following increased Rho signaling. These developmentally normal cells also show increased migration along nanotopographic cues in the same manner as GBM cells, presenting evidence that glioma cells are migrating in a manner reminiscent of radial migration in corticogenesis, an idea that has been previously explored ([@B9]). Radial glia cells in the developing brain present long, linear processes along which neural progenitor cells migrate to exit the stem cell niche and enter developmental areas of the brain. These similarities between radial glial and glioma migratory behavior are consistent with the notion that that cancer mirrors embryogenesis pathways ([@B56]) through the epigenetic reactivatioon of embryonically active genes ([@B3]; [@B122]). Based on these similarities, it is possible that the down-regulation of RhoA that initiates cell migration in corticogenesis has similar mechanisms to the same phenomenon observed in glioma invasion. While RhoA down-regulation is required for migration in corticogenesis, RhoA is still required at low levels, implying a biphasic dependence on RhoA. Consistently, it was found that myosin II, which is activated downstream in the Rho-ROCK pathway, may biphasically affect migration in astrocytomas. Low concentrations of a myosin II inhibitor increased migration, whereas higher concentrations inhibited migration ([@B99]). Another group found that glioma cells that can migrate on compliant substrates became sensitive to substrate stiffness when myosin-generated contractile force was increased through RhoA or ROCK activation ([@B120]), suggesting that the biphasic RhoA/myosin II dependence could underlie the different sensitivity of glioma subtypes to substrate stiffness that was discussed earlier. It was also found that mice with implanted tumors expressing constitutively active RhoA had a 30% increase in mean survival time, providing the basis of a possible clinical application ([@B120]).

The Arp2/3 complex is an actin nucleator involved in the cytoskeletal remodeling necessary for lamellipodia protrusion and is activated downstream from Rac. Formins, on the other hand, are involved in unbranched actin assembly, including stress fibers and filopodia. These different actin nucleators have been reviewed in more detail ([@B13]). Not much evidence has been gathered to define the role of different actin nucleators in glioma invasion. The mechanical confinement theory for nanotopography-induced migration of glioblastoma cells was shown to be formin dependent, however, while Arp2/3 independent ([@B70]). Another group showed that the Arp2/3 complex contributes significantly to glioma cell migration, although the drug used in this work only allowed observation for a short duration before cytotoxic effects ([@B61]). Finally, a recent paper showed that GBM invasion was hindered by a drug that disrupts actin polymerization in a method that was not reliant on Arp2/3, although formin reliance was not investigated ([@B44]).

Transmembrane receptors
-----------------------

Integrins mediate the adhesion to and migration along many common ECM proteins, such as collagens, fibronectin, and laminin (Barezyk *et al*., 2010), which are found in the perivascular region in the brain. In the brain parenchyma, CD44 is considered the transmembrane receptor held primarily responsible for cell adhesion to the HA-rich ECM ([@B68]). Both integrins and CD44 have been extensively studied in cancer and play a significant role in the invasive behavior of malignant gliomas.

Integrin antagonists have been used to target HGGs and GBMs ever since cilengitide was first synthesized in the early 1990s as an RGD peptide-based competitive inhibitor of integrin binding to native RGD sequences in the ECM ([@B66]). Cilengitide treatment alone did not result in any significant inhibition of tumor growth; however, combined treatment with cilengitide did enhance radiotherapy efficacy in vitro ([@B18]), showing its potential as a treatment component, if not a stand-alone treatment. Unfortunately, this potential did not translate to clinical testing, with no survival benefit being observed ([@B106]). This has resulted in a string of new integrin inhibitors being studied, including several other RGD-based treatments (reviewed by [@B26]) with promising in vitro results. Another recent integrin antagonist is GLPG0187, which was shown to cause detachment and cell death of mouse glioma tumor cells ([@B105]). While clinical trial results for these new integrin antagonists have yet to be released, a possible explanation for cilengitide failure is that glioma cells are capable of migrating not just perivascularly, but also down the white matter tracts using CD44 as a transmembrane receptor for the HA-rich environment, which would not be inhibited by these integrin antagonists.

In the study of CD44 in GBM invasion, a variety of models have been used, in addition to the widely used brain slice model. One group studied invasion in the astrocyte-rich brain stroma by culturing astrocytes to hyperconfluence before plating GBM cells ([@B43]). In this method, astrocytes develop a 3D scaffold that self-assembles an ECM that is presumably similar to that assembled in the brain. Other groups have modeled migration using HA-RGD hydrogels (Ananthanarayanan *et al*., 2011) and between an HA hydrogel and an ECM protein-coated surface ([@B90]) as substrates. More recently, a method was developed that elegantly models multiple steps of invasion by embedding a cell reservoir in a 3D HA-RGD matrix featuring an open channel, representing bulk tumor, brain parenchyma, and the vasculature, respectively ([@B119]). This model, though simple, was able to elicit the multiple-step invasive process described in vivo, with migration occurring through the matrix via long extended processes, followed by rapid migration along the vasculature.

Despite the multiple methods developed to study the importance of CD44 in GBM invasion, data has been reported on the importance of CD44 expression levels on glioma migration and its effects on patient survival, with different groups claiming it has positive, negative, or no impact on GBM invasion. These apparent contradictions were reconciled when a recent paper showed that survival, as well as glioma migration speed, depends biphasically on CD44 expression ([@B58]). As the authors of this study note, these findings correlate with previous work that showed that migration depends biphasically on cell-ECM adhesion strength ([@B31]). They also showed that CD44 expression varies for different glioma subtypes, with proneural subtypes expressing lower CD44 levels, intermediate expression found in proliferative subtypes, and highest expression in mesenchymal subtypes. Fastest migration occurs with intermediate expression levels. They also note that this complicates potential CD44 antagonist-based therapies, as decreasing CD44 levels or availability in the mesenchymal subtype (one of the most common glioblastoma subtypes \[[@B87]\]) would lead to increased migratory speed and worsened patient prognosis. Clarifying the relative importance and different functions of CD44 and integrins in glioma cell migration could inform the development of glioma therapies that target these transmembrane receptors. Also, in addition to its role in adhesion, CD44 has been shown to promote the GBM stem-like phenotype and contribute to radiation resistance ([@B88]. The role of CD44 in glioma invasion is reviewed in further detail by [@B71].

CONCLUSION
==========

Although significant progress on blocking various mechanisms involved in cell migration has resulted in reduced glioma invasiveness in vitro, these findings have not translated to prolonged survival of HGG patients. This may be due to the fact that most studies in vitro explored only a single target, while many other mechanisms exist and are utilized in vivo. Approaches targeting combinations of varying migratory mechanisms, such as combining CD44 and integrin antagonists, have not been extensively explored to date and may produce a more effective treatment. Targeting multiple key players in migration concurrently, such as transmembrane receptors and cytoskeletal remodeling pathways, is another logical pathway to explore. Another reason for the lack of clinical success could be that diffuse migration of glioma cells commonly occurs before diagnosis, so that arresting migration would not lead to less invasion or increased success of localized treatments. Future work on early detection and targeting a full range of migratory mechanisms to halt the migration of heterogeneous glioma cells may lead to clinical success.
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